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Abstract
Background: Polycystic ovary syndrome (PCOS) is a common, reproductive endocrinopathy associated with serious
short and long term health risks. Many women with PCOS use ingestible complementary medicines. This systematic
review examined the effect on menstrual regulation and adverse effects from randomised controlled trials.
Methods: Randomised controlled trials (RCTs) that compared herbal or nutritional supplements to placebo or active
controls in women with PCOS were eligible for inclusion. Electronic databases were searched to July 2017. Study selection
and assessment of quality were conducted independently by two review authors.
Results: Twenty four studies (1406 women) investigating seven nutritional supplements and four herbal medicines were
included. No one study was assessed as having a low risk of bias. Four trials reported on the primary endpoint menstrual
regulation. There was no evidence on improved menstrual regularity for calcium plus vitamin D compared to Metformin
(RR: 0.66, 95% CI 0.35 to 1.23, p = 0.19), reduced amenorrhoea for Camellia sinensis compared to placebo (RR: 0.17, 95% CI
0.02 to 1.72, p = 0.13) and no difference in the number of menses per month for Cinnamomum sp. against placebo (MD
0.05, 95% CI -0.36 to 1.36, p = 0.26).
Adverse effects were investigated in seven studies (164 women). Mild adverse effects were found for Cinnamomum sp.
compared to placebo (17 women, RR: 0.36, 95% CI 0.03 to 0.70, p = 0.03). No difference was found for adverse effects
between inositol, B complex vitamins, vitamin D, chromium and placebo. Improved reproduction, metabolic hormones
and hyperandrogenism was found for inositol and improved cholesterol for omega three fish oils.
Conclusion: There is no high quality evidence to support the effectiveness of nutritional supplements and herbal medicine
for women with PCOS and evidence of safety is lacking. High quality trials of nutritional supplements and herbal medicines
examining menstrual regulation and adverse effects in women with PCOS are needed.
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Background
Polycystic ovary syndrome (PCOS) is the most common
female reproductive endocrine disorder [1] estimated to
affect up to one in five women [2]. PCOS has broad health
implications including adverse metabolic (obesity, type
two diabetes, cardio vascular disease), reproductive (infer-
tility, miscarriage, pregnancy and neonatal complications)
[3, 4], and psychological (anxiety, depression and stress)
[5, 6] risks. The pathogenesis is underpinned by insulin re-
sistance [7] which affects up to 75% of lean women and
up to 95% of obese women (compared to 62% in BMI
matched non-POCS controls) [8]. Prevention and reduc-
tion of being overweight with lifestyle interventions is
first-line evidence-based treatment [9], however the
strength of evidence for lifestyle is limited by high attrition
in randomised controlled trials (RCTs) [10, 11] and, as in
the general population, engagement and adherence to life-
style intervention is impacted by psychosocial and physical
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barriers in women with established obesity [10]. Add-
itional treatments for PCOS symptoms include pharma-
ceutical agents [9] (contraceptive pills (OCP) and
hypoglycaemics), but contraindications for the OCP are
common in overweight women [12] and hypoglycaemic
agents are associated with significant rates of unpleasant
side effects [13, 14], potentially worsening women’s quality
of life. Women with PCOS have been shown to seek out
alternative [15] and adjunct treatments including comple-
mentary medicines (CM) to improve their health, fertility
and wellbeing [16].
There is some evidence of positive effects in women
with PCOS for ingestible CMs including nutritional sup-
plements [17, 18] and herbal medicines [19, 20]. Women
with PCOS have significantly higher levels of homocyst-
eine and oxidative stress [21] and nutritional supple-
ments have demonstrated efficacy in women with PCOS
[18] and risk reduction for the same conditions in other
populations [22]. Endocrine mechanisms of herbal medi-
cine may improve hormone balance in PCOS and may
positively effect menstural regularity [23, 24], a critial
outcome of concern for women with PCOS [25]. This
study aimed to synthesise the evidence of effectiveness
and safety for herbal and nutritional supplements in
women with PCOS.
Methods
RCTs that compared herbal medicines or nutritional
supplements to placebo, active controls (nutritional sup-
plements) or usual care (pharmaceutical treatment, life-
style management) were sought. Cross-over trials were
included for completeness but data from the first phase
only were included in meta-analyses.
Participants were women aged between 18 and 44 with a
diagnosis of PCOS according to the Rotterdam Criteria
(2003), [26] or the National Institute for Health (NIH) [27].
Nutritional or herbal supplements were defined as
herbal extracts in a single preparation and/or tablets
containing vitamins, minerals or dietary derived mole-
cules designed to improve symptoms associated with
PCOS and not medically prescribed for conditions of
deficiency [28].
The primary outcome measures were; ‘menstrual regu-
larity’ defined as number of women with menstrual
cycles of 22 to 35 days duration, number of women with
amenorrhoea and number of menses per month, and
‘adverse effects’. Secondary outcomes were; secondary
menstrual characteristics (ovulation, presence of a
dominant follicle, ratio of luteal weeks, gonadotropin
hormones), polycystic ovaries, pregnancy rates and out-
comes (live births and miscarriage), hyperandrogenism
(clinical and biochemical), anthropometric factors, meta-
bolic biochemistry, PCOS associated risk factors, quality
of life and anxiety and depression.
All published and unpublished RCTs comparing herbal
medicine or nutritional supplements with active controls,
usual care or placebo, in English language, were searched.
Electronic databases included Cochrane central register of
controlled trials (CENTRAL), the Cochrane Library,
MEDLINE ovidSP, CINAHL, SciVerse, EMBASE, PubMed
were searched from the date of inception to July 2017.
Reference lists of review articles and texts were searched
by hand.
Keywords were ‘polycystic ovary syndrome’, ‘PCOS’,
‘ovarian cysts’, ‘hyperandrogenism’, ‘hirsutism’, ‘acanthosis
nigrans’, ‘acne’, ‘oligomenorrhoea’, ‘amenorrhoea’, ‘oligo-
ovulation’, ‘anovulation’, ‘menstrual disorders’, ‘menstrual’,
‘ovulation’, ‘fertility’, AND ‘alternative’, ‘integrative medi-
cine’, ‘complementary medicine’, ‘naturopathy’, ‘natural’,
‘herbal medicine’, ‘botanical medicine’ ‘phytomedicine’,
‘phytotherapy’, ‘herbs’, ‘diet’, ‘food’, ‘nutritional’, ‘nutrient’,
‘micro’, ‘dietary’, ‘vitamin’, ‘mineral’, ‘supplements’, ‘hyper-
vitamin’, AND ‘randomis(z)ed. control trial’, ‘clinical trial’
and ‘RCT’.
Study characteristics, risk of bias and outcome data
were manually extracted independently by two (of three)
authors (CAS, JAA and SA) and entered onto data ex-
traction forms adapted from the Cochrane Collaboration
[29] for systematic critical appraisal. Differences of opin-
ion were resolved by consensus. Risk of bias was
assessed as high, low or unclear risk for randomization
(generation of randomized schedule and allocation se-
quence), performance (blinding of participants), detec-
tion (blinding of outcome assessors and data analysts),
attrition (reporting missing data), reporting (pre-speci-
fied and or relevant outcomes) and other areas of poten-
tial bias including factors unique to particular settings
(such as study being stopped early, apparent fraudulent
reporting (including the absence of declaration of fund-
ing and conflicts of interest in relation to authors affilia-
tions) or extreme baseline imbalance) [29].
Analyses were conducted using Review Manager (Rev-
Man) 5.3 [30]. Dichotomous data were expressed as rela-
tive risks (RR) and normally distributed continuous data as
mean differences (MD). Corresponding 95% confidence
intervals (CIs) and p values were calculated. Heterogeneity
between studies was investigated by the I2 statistic (I2 of
more than 50% was considered indicative of heterogeneity),
the P value from the χ2 test and by visual inspection of the
forest plots. For non-significant heterogeneity, results were
pooled in a fixed effect model and the effects were adjusted
using random effects where there was significant hetero-
geneity. If distributions were skewed and results reported
as the median and range, with non-parametric tests of
significance, the results were excluded from the meta-
analysis. Androgens, cholesterol and triglycerides were
converted to common measurements for comparison and
the mean difference (MD) was calculated.
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Results
A total of 116 records were identified through the elec-
tronic and manual searches. Following initial screening,
63 articles were retrieved for detailed evaluation (Fig. 1).
Thirty two full text articles were excluded as they did not
meet the inclusion criteria (detailed in Additional file 1:
Table S1). Following detailed evaluation of 31 full text
studies, a further seven studies were excluded due to not
investigating key signs and symptoms of PCOS, not being
randomised or not including participants with a clinical
diagnosis (detailed in Additional file 1: Table S1). Twenty
four randomised controlled trials met the inclusion
criteria [31–54] including 1406 women.
Included studies
Design
The sample sizes ranged from 10 [43] to 283 [37]. All
studies were conducted at university hospitals or clinical
research centres in America [42, 43, 46, 51, 52],
Australia [35], Egypt [49], Hong Kong [33], Iran [32, 40,
44, 47, 48, 50, 54], Italy [31, 34, 36–38], Turkey [53],
United Kingdom [39] and Venezuela [41, 45].
Participants
Five studies included overweight participants (BMI
greater than 25) [33, 35, 44, 45, 51], and two studies in-
cluded women of normal bodyweight [36, 41]. One study
stratified randomization according to BMI (overweight
or normal weight) [47]. Seventeen studies excluded par-
ticipants with other endocrine disease [42, 46, 53, 54]
and elevated serum prolactin (PRL) [31–33, 35, 37, 38,
41, 44, 46–48, 50–52].
Interventions
Seven nutritional supplements and four herbal medi-
cines were investigated (Table 1).The treatment dura-
tions ranged from thirty days [39] to seven months [49]
with most treatment durations (13 studies) of eight to
twelve weeks (Table 1). Inositol was investigated in eight
studies and three investigated omega three fish oils.
Calcium plus vitamin D, vitamin D alone, selenium and
Cinnamomum sp. were investigated in two studies and
nutritional supplements B complex vitamins, chromium,
and herbal medicines Camellia sinensis, Mentha spicata
and Cimicifuga racemosa were investigated in single
studies. Calcium plus vitamin D, B complex, inositol,
Fig. 1 PRISMA (flow chart) diagram
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Table 1 Interventions: Nutritional supplements and herbal medicine
Reference Dose Control Duration
Omega 3 fish
oils
Cussons A J; Watts GF; Mori
TA; Stuckey BGA. 2009 [34]
4000 mg per day EPA 675 mg; DHA
1400 mg
(Ocean nutrition® by Halifax, Nova
Scotia, Canada)
Placebo Olive oil 4000 mg
(Cardinal Health Australia, Vic Australia)
8 weeks
Mohammadi E; Rafraf M;
Farzadi L; Asghari-Jafarabadi M;
Sabour S. 2012 [43]
4000 mg omega 3 (EPA 720 mg; DHA
480 mg)
(Good Health Company, USA)




Vargas LM; Almario RU; Buchan
W; Kim, K; Karakas SE. 2011 [50]
3500 mg (EPA: 2450 mg; DHA:
1210 mg)
(Nordic Naturals Watsonville, California)
Placebo (soybean oil 3500 mg)
(Nordic Naturals, Watsonville California)
6 weeks
Chromium Lucidi SR; Thyer AC; Easton CA;
Holden AEC; Schenken RS;
Brzyski RG. 2009 [42]
Chromium picolinate 200mcg per day
(manufacturer not reported)
Placebo
(type or manufacturer was not
reported)
16 weeks
Selenium Hosseinzadeh F; Hosseinzadeh-
Attar M; Yekaninejad J; Saeed
M; Rashidi B. 2016 [39]
Selenium 200mcg per day
(Nature Made Pharmaceutical Company,
California USA)
Placebo (type not specified)
(Roshd Pharmaceutical Incubation
Centre, Tehran University, Iran)
12 weeks
Razavi M; Jamilian M; Kashan
Z; Fakhrieh HZ;
Mohseni M; Ghandi Y;
Bagherian T; Asemi Z 2015 [47]
Selenium 200mcg plus Metformin
1500 mg per day
(Nature Made Pharmaceutical Company,
California USA)
Placebo (cellulose) plus Metformin
1500 mg per day(Barij Essence
Pharmaceutical Company, Iran)
8 weeks
Vitamin D Ardibilli HR; Gargari BG;
Farzadi L. 2012 [31]
Vitamin D. Three oral treatments of
50,000 IU per 20 days (D-vitin® by
Zahravi Pharma Company, Iran)
Placebo, One tablet every 20 days
(Zihravi Pharma Company, Iran)
2 months
Raja-Khan N; Shah J; Stetter
CM; Lott MEJ; Kunselman AR;
Dodson WC; Legro RS. [45]
Vitamin D 12000 IU per
day(Cholecalciferol in soy lecithin)
(Maximum D3® by BTR Group, USA)
Placebo per day (soy lecithin without




Rashidi R; Haghollahi F;
Shariat M; Zayerii F. 2009 [46]
Calcium 1000 mg + vitamin D 400mcg
per day
(Cal D tablets by Tehran Derou, Iran)
Metformin 500 mg, three times per day
(Minoo Darou, Iran)
12 weeks
Tehrani, HG; Mostajeran F;
Shahsavari S. 2014 [49]
Calcium 1000 mg (Osvah
Pharmaceuticals)








Kilicdag EB; Bagis T; Tarim E;
Aslan E; Erkanli S; Simsek E;
Haydardedeoglu B; and Kuscu
E. 2005 [52]
B1: 500 mg; B6: 500 mg; B12: 2000mcg
+Metformin 1700 mg/day, (Apikobal®
by Santa Farma Turkey) (Glugophage®
by Merke, Turkey)
Metformin 1700 mg/day




Artini PG; Di Berardino OM;
Papini F; Genazzani AD; Simi G;
Ruggiero M; Cela V. 2013 [30]
Inositol 2 g and folic acid 200 mg plus
folic acid 200mcg
(Inofert® by Ital Pharmaco, Milano, Italy)
Folic acid 400mcg daily
(Inofert® by Ital Pharmaco, Milano, Italy)
12 weeks
Costantino D: Minozzi G;
Minozzi F; Guaraldi C. 2009 [33]





Dona G; Sabbadin C; Fiore C;
Bragadin M; Giorgino FL;
Ragazzi E; Clari G; Bordin L;
Armanini D. 2012 [35]
Inositol 1200 mg/day as powder,
pre-dosed presented in sachets
dissolved in water (manufacturer
not reported)
Placebo
(matched powder type or manufacturer
not reported)
12 weeks
Gerli M; Mignosa; Di Renzo GC.
2003 [36]
Inositol 200 mg
(Gestosan®LO.LI. Pharma, Rome, Italy)
Placebo matched to Gestosan®.
(Type or manufacturer not reported)
20 weeks
Gerli E; Papaleo A; Ferrari GC;
Di Renzo GC. 2007 [37]
Inositol 4 g plus folic acid 400mcg




Iuorno MJ; Jakubowicz DJ;
Baillargeon JP; Dillon P; Gunn
RD; Allan G; Nestler JE 2002 [40]
Inositol (chiro) 600 mg
(INS-1® by Insmed pharmaceuticals,
Richmond, Virginia, USA)
Placebo
(type or manufacturer not reported)
6–8 weeks
Jamilian M; Farhat P;
Foroozanfard F; Ebrahimi FA;
Aghadavod E; Bahmani F;
Badehnoosh B; Jamilian H;
Asemi Z [54]
Inositol 4 g + folic acid 400mcg
(LO.LI. Rome, Italy)
Metformin
(Tehran Darou Pharma. Tehran, Iran)
12 weeks
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selenium and Cimicifuga racemosa were compared with
pharmaceutical controls (metformin and clomiphene
citrate) [47–50, 53, 54].
Outcomes
Four studies reported on the primary outcome, menstrual
regularity [33, 42, 47, 50]. Seven trials reported on adverse
effects (164 women) [41–43, 45, 46, 52, 53]. Seven studies
reported on secondary menstrual cycle characteristics [34,
37, 38, 41, 45, 49, 50]. One trial reported on polycystic
ovaries [49]. Three studies reported on pregnancy rates
[47–49] and one on miscarriage [49]. Fourteen trials re-
ported on the outcomes of biochemical hyperandrogenism
[31, 33–36, 39–43, 45, 48, 51, 54]. Four trials reported on
the outcomes of clinical hyperandrogenism with validated
tools including the modified Ferriman Gallwey score to
measure degree of hirsutism [39, 48, 50, 54], and acne with
the dermatology quality of life index for health related
quality of life [39]. Eight trials reported anthropometric
outcomes of participants [33, 37, 38, 44, 50, 52–54].
Eighteen trials reported metabolic biochemistry including
fasting glucose and insulin [31–38, 40–46, 51–53].
Risk of bias for included studies
All 24 studies were assessed as having some risk of bias
(Fig. 2). Incomplete or poor reporting by most trial
authors impacted on the assessment, and consequently
an unclear risk of bias for at least two characteristics
was determined in 23 studies [31–52, 54]. Seven studies
were found to have high risks of bias in at least three
domains including performance [49–51, 54], detection
[49, 50, 54], attrition [37, 38, 51, 53], reporting [37, 38,
50, 53] and other forms of bias [37, 38, 49–51, 53, 54].
Fourteen studies were at high risk for other sources of
bias including nine with imbalanced baseline character-
istics [31, 33, 37, 38, 40, 41, 43–45, 54], insufficient time
to detect change [32, 34, 39], and an active control re-
ported as placebo (placebo consisted of lecithin which is
a natural source of inositol [55]) [17]. Three studies did
not report the effect of high attrition (over 30%) on
baseline menstrual characteristics in the test and control
groups [37, 38, 42]. Twelve studies declared conflicts of
interest [31, 32, 35, 36, 42, 44–46, 48, 49, 51, 54]. Ten
studies reported no conflicts of interest and two studies
reported potential conflicts of interest due to authors’ af-
filiations [46; 45]. Fourteen studies reported sources of
study funding [32, 35, 36, 40–49, 51]. Three studies were
funded with grants from the pharmaceutical industry
[35, 41, 45], twelve studies were funded by university or
research institute grants [32, 36, 40, 42–49, 51] and one
study was funded by both pharmaceutical industry and
an institute grant [45].
Table 1 Interventions: Nutritional supplements and herbal medicine (Continued)
Reference Dose Control Duration
Nestler JE; JakubowczDJ;
Reamer P; Gunn R; Allan G.
1999 [44]
Inositol 1200 mg labelled according to
subject number
(INS-1® by Insmed pharmaceuticals,
Virginia, USA)
Placebo Labelled and packaged at




Camellia sinensis Chan CW; Marcel Koo MWL;
Ng EHY; Tang OS; Yeung WSB,
Ho P-C. 2006 [32]
Camellia sinensis tea infused in boiled
water for 30 mins, freeze dried and
encapsulated. Epigallocatechin (EGCG)
standardised to 373.92 mg ± 20.57,
equivalent to 1.5 cups of tea.
Placebo capsules





Shahin AY; Mohammed SA.
2014 [48]
120 mg Cimicifuga extract plus
clomiphene 150 mg on menstrual cycle
days 3–7, trigger injection (10,000 IU,
intramuscular Human Chorionic
Gonadotropin) and progesterone
supplementation (50mcg per day for
two days following trigger injection)
(Klimadynon® Bionorica, Neumarkt,
Germany)
(Pregnyl, Organon, Holland, The
Netherlands)
Clomiphene, 150 mg per day
administered on menstrual cycle
days three to seven, a trigger injection
(HCG) and progesterone support
(50mcg per day for two days following
trigger injection).






Cinnamomum sp. Wang JG; Anderson RA;
Graham GM; Chu MC
2007 [51]




(Type or manufacturer were not
reported)
8 weeks
Kort DH; Lobo RA. 2014 [41] Cinnamomum sp. 1500 mg per day





Mentha spicata Grant, P. 2009 [38] Tea bags standardised content of dried
Mentha spicata leaves. Uniform
instructions for preparation provided to
participants
Chamomile tea uniform preparation
instructions provided.
30 days
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Effects of interventions
Data from two trials were not included in analyses. One
trial used a cross-over trial design and did not report
first phase outcomes [35]; the other study reported out-
comes as the median rather than the mean [33]. Where
data could not be included in a meta-analysis a narrative
reporting of the findings was presented.
Nutritional supplements for PCOS
Calcium plus vitamin D Two trials (78 women) com-
pared calcium plus vitamin D with metformin for the num-
ber of women with regular menstrual cycles (21–35 days)
[47, 50]. There was no evidence of an improved effect (RR
0.66, 95% CI 0.35 to 1.23, p = 0.19, I2 0%). Adverse effects
were not reported.
Secondary outcomes
Rashidi and colleagues reported on the number ovarian
cysts defined as immature follicles (diameter 5-9 mm) and
pregnancy rates for calcium plus vitamin D against met-
formin [47]. No difference between groups was found.
Tehrani and colleagues reported on BMI and hirsutism
(defined as Ferriman Gallwey score over 8) [50]; no differ-
ence was found between groups.
Vitamin B complex One study investigated B complex
vitamins plus metformin compared with metformin
alone, for 32 women [53]. Results were reported as
‘women taking Metformin’ and between group differ-
ences were not reported. No data were available for B
complex vitamins on menstrual regularity. No difference
for adverse events was found.
Secondary outcomes
Four secondary outcomes for vitamin B complex plus
metformin were reported. No significant effects were
found for pregnancy rates, waist to hip ratio or HOMA-IR.
Inositol (vitamin B8) No trials reported on the primary
outcome menstrual regularity for inositol (Table 2). Two
trials (64 women) reported on adverse events for inositol
[41, 45]. No adverse effects were found for inositol
against placebo [41, 45].
Secondary outcomes
Significant benefits were found for inositol versus pla-
cebo and active controls (90 women) for the secondary
outcomes of reproductive characteristics and hyperan-
drogenism (Fig. 3) and (Table 2).
The number of ovulations was significantly higher for
women taking inositol (two studies, 64 women, RR 3.13,
95% CI 1.68 to 5.83, p < 0.001). Two trials reported on a
subgroup of women wanting to conceive (84 women)
[37, 38] and a third trial included women preparing to
undergo medically assisted fertility treatment (50
women) [31]. Meta analyses of these three studies (134
Fig. 2 Risk of Bias summary
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effect MD or RR
95% CI p value
Hyperandrogenism
Free testosterone nmol/l 55 51 3 [22, 23, 30]
0%, p = 0.94
MD −0.02 −0.10 to 0.06 0.62
Total testosterone** nmol/l 103 89 5 [34, 36, 41, 45, 54]
32%, p = 0.0009
MD 0.99 −1.54 to −0.44 < 0.001
Androstenidione nmol/l 73 59 4 [22, 23, 30, 37]
0%, p = 1.0
MD 3.59 −4.62 to −2.55 < 0.001
Sex hormone binding globulin
(SHBG) nmol/l
55 67 2 [22, 23]
0%, 0.50
MD 40.67 25.83 to 55.50 < 0.001
Modified Ferriman Gallwey score 30 30 1 [54] MD 0.90 −1.18 to 2.98 0.40
Reproduction
Number of days to ovulation
(number of days)
181 194 2 [24, 25]
0%, p = 0.90
MD 17.7 −31.4 to −4.1 0.01
Ratio of luteal week to total trial luteal
weeks: total trial weeks
166/697 140/1000 2 [24, 25]
0%, p = 0.90
RR 1.7 1.39 to 2.08 < 0.001
Number of ovulations 25/32 8/32 2 [22, 23]
0%, p = 0.95
RR 3.13 1.68 to 5.83 0.001
Number of women who did not ovulate 16/181 34/194 2 [24, 25]
0%, p = 0.95
RR 0.5 0.29 to 0.86 0.01
Pregnancy 18/71 6/63 3 [24, 25, 36]
0%, p = 0.95
RR 2.78 1.19 to 6.5 0.02
Live births 8/25 3/25 1 [36] RR 2.67 0.80 to 8.90 0.11
FSH mIU/l 25 25 1 [36] MD 1.4 −1.63 to −1.17 0.001
LH mIU/l 25 25 1 [36] MD 3.5 −4.9 to −2.1 0.001
FSH:LH ratio 25 25 1 [36] MD 0.4 −0.68 to −0.12 0.006
Anthropometric
BMI*** 48 38 2 [37, 54] MD −0.30 −1.10 to 0.50 0.46
57 57 3 [22, 23, 36]
I2 31%, p = 0.24
MD 0.40 −0.07 to −0.86 0.86
Waist to hip ratio 32 32 2 [22, 23]
0%, p = 0.32
MD −0.02 −0.03 to −0.01 0.01
Metabolic hormones
Fasting glucose mmol/l 73 59 4 [22, 23, 30, 37]
0%, P = 0.52
MD 1.17 −1.72 to – 0.63 < 0.001
Fasting insulin μU/ml 73 59 4 [22, 23, 30, 37]
18%, p = 0.30
MD 2.7 −3.9 to −1.5 < 0.001
HOMA-IR**** 25 25 1 [36] MD −1.30 −1.60 to −1.00 < 0.001
18 8 1 [37] MD −0.60 −0.89 to – 0.30 < 0.001
Risk factors
Cholesterol mmol/l 32 32 2 [22, 23]
27%, p = 0.24
MD 0.56 −1.07 to −0.04 0.04
Triglycerides mg/dL 32 32 2 [22, 23]
8%, p = 0.30
MD 31.6 −61.1 to −2.0 0.04
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women) demonstrated pregnancy rates were significantly
higher for women taking inositol compared to controls
(RR 2.8, 95% CI 1.2 to 6.5, p = 0.02).
Significant benefits were found for the secondary out-
comes of total testosterone, (five studies, 192 women, MD
0.99 nmol/l, 95% CI -1.54 to −0.44, p < 0.001) [34, 36, 41,
45, 54] (Fig. 3) and androstenidione (four studies, 132
women, MD 3.59 nmol/l, 95% CI -4.6 to −2.6, p < 0.001)
[34, 36, 41, 45] and SHBG (two studies, 122 women, MD
40.67 nmol/l, 25.8 to 55.5, p < 0.01) [41, 45]. No significant
benefit was found for free testosterone following treat-
ment with inositol [34, 36, 41, 45] or for clinical hyperan-
drogenism (Ferriman Gallwey score) for inositol
compared with metformin [54].
Significant benefits were found for fasting glucose
(four trials, 132 participants, MD-1.17, 95% CI -1.72 to
−0.63, p < 0.01), [34, 36, 41, 45]; fasting insulin (four tri-
als, 132 participants, MD −2.7 μU/ml, 95% CI -3.9 to
−1.5, p < 0.01) [34, 36, 41, 45] and reduced insulin resist-
ance (HOMA-IR) (two trials, 76 participants, MD -1.3,
95% CI -1.6 to −1.0, p < 0.01) [31, 36] (Table 2). Signifi-
cant heterogeneity was found for the two trials investi-
gating inositol for HOMA-IR (I2 = 91%, p < 0.001) and
effects were adjusted using a random effects model.
Study heterogeneity was likely due to different
characteristics of participants at baseline (normal weight
[36] and overweight [31]), different doses of inositol and
types of controls (1200 g per day versus placebo [36]
and 2 g plus folic acid versus folic acid alone [31]).
Significant benefits were found for the secondary out-
come waist to hip ratio (two studies, 64 women, MD
-0.02, 95% CI -0.03 to −0.01, p = 0.01) [41, 45]. Mixed
results were found for inositol with BMI in five trials
[31, 36, 41, 45, 54] (Table 2). One trial showed signifi-
cant improvements in BMI [36], whilst three others
found no significant difference between groups [31, 45,
54]. A fifth trial found significantly increased BMI for
women taking inositol compared to placebo controls
however this study included lean participants and mean
BMI at endpoint remained within normal BMI range
(22.3 ± 0.3) [41]. Significant heterogeneity of trials pre-
vented meta-analysis (I2 = 89%, p < 0.00001). The high
heterogeneity may be explained clinically with variable
baseline BMI categories of participants ranging from
normal [36, 41, 54], overweight [31, 54] and obese [45].
Dose variation of inositol may have also contributed to
study heterogeneity with daily doses of 600 mg [41],
1200 mg [36, 45] and 2 g [31] [36]) and durations of treat-
ment for six [41, 45] and twelve weeks [31, 36, 54]) [54].
Significant benefits were found for total cholesterol (two










effect MD or RR
95% CI p value
HDLmg/dL 22 22 1 [22] MD 0 −4.73 to 4.73 1.0
LDL mg/dL 22 22 1 [22] MD −2.0 −13.7 to 9.7 0.74
CRP 30 30 1 MD −2.2 −3.57 to −0.83 < 0.01
*calculated for dichotomous outcomes only
**five trials with significant heterogeneity (I2 = 75%, p = 0.003) following analyses incorporating random effects
***five trials with significant heterogeneity (I2 = 89%, p < 0.0001) following analyses incorporating random effects, and not combined
**** two trials with significant heterogeneity (I2 = 91%, p-0.0009) following analyses incorporating random effects, and not combined
Fig. 3 Meta-analysis inositol versus placebo for total testosterone in women with PCOS
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trials, 64 women, MD 0.56 mmol/l, 95% CI -1.07 to −0.04,
p = 0.04) [41, 45] and triglycerides (two trials, 64 women,
MD 31.6 mg.dl, 95% CI -61.1 to −2.0, p = 0.04) [41, 45]
following treatment with inositol compared to placebo
controls. Reduced inflammation (c-reactive protein (CRP))
was found for inositol compared to metformin in one
study (MD -2.2, 95% CI -3.57 to −0.83, p < 0.01) [54].
Chromium supplements One small study reported on
chromium compared to placebo in ten women with
PCOS [43]. The study did not report on menstrual regu-
lation. No adverse events were reported for either chro-
mium or placebo. Five secondary outcomes free
testosterone, total testosterone, ovulation, FSH and LH
were reported. No significant treatment effects were
found for any outcomes.
Vitamin D Two RCTs examined vitamin D supplements
compared with a placebo in 78 women with PCOS [32,
46]. Heterogeneity of studies was not significant (I2 = 0%)
and data were pooled for analyses. The effects of vitamin
D on menstrual regulation were not reported. No adverse
effects were found in one study [46].
Secondary outcomes
No significant treatment effect was found for vitamin
D compared with placebo for metabolic hormones in-
cluding fasting glucose, fasting insulin, insulin resistance
or insulin sensitivity [32, 46]. One study including 28
women found no evidence of improvements for vitamin
D compared to placebo for free and total testosterone,
cholesterol and high and low density lipoproteins triglyc-
erides and inflammation (CRP) [46].
Omega three fish oils Two studies investigated omega
3 supplements against placebo in 95 women [44, 51].
Neither study reported on menstrual regulation or
adverse effects.
Secondary outcomes
A significant effect was found for the risk marker total
cholesterol in women receiving omega 3 fish oils com-
pared to placebo controls (two trials, 95 women,
−0.49 mmol, 95% CI -0.62 to −0.35, p < 0.001) [44, 51]
(Fig. 4).
No evidence of an effect was found for free testoster-
one or SHBG [51], waist to hip ratio [44] or for inflam-
mation (CRP) [44]. Findings were mixed for some
secondary outcomes including triglycerides, HDL and
LDL [44, 51], BMI [44, 51], fasting glucose and insulin
resistance [44, 51]. Clinical heterogeneity was likely due
to the dose of omega three. One trial received treatment
of 3.5 g (EPA 258 mg and DHA 242 mg) for six weeks
[51], which was less than the other trial where women
received 4 g (EPA 720 mg and DHA 480 mg) over eight
weeks and additionally due to wide variation in mean
BMI at baseline. Both trials included women with a BMI
that ranged between 25 and 40–45 however the mean
BMI for women in one trial was in the overweight
category (BMI 28) [51] compared to morbidly obese (BMI
36) in the other [44]. Significant effects were found for
morbidly obese women taking the higher dose of fish oils
[44] for fasting glucose (−0.33 mmol/l, 95% CI -0.26 to
−0.40, p < 0.001), insulin resistance (HOMA-IR) (−1.23,
95% CI -1.6 to −0.86, p < 0.001) and reduced LDLs (−0.88,
95% CI -1.04 to −0.72, p < 0.01) [44].
Selenium Two studies investigated selenium supple-
ments against placebo in 109 women [40, 48]. One in-
vestigated added metformin in both study groups [48].
Neither menstrual regulation nor adverse effects were
investigated in either study.
Secondary outcomes
A significant effect was found in one study for selen-
ium against placebo in 53 women for fasting glucose
(MD 4.66 mg/dl, 95%CI 3.23 to 6.09, p < 0.00001), insu-
lin resistance (HOMA-IR) (MD 0.24 95%CI 0.06 to 0.42,
p = 0.008), total testosterone (MD 0.18 ng/ml, 95%CI
0.09 to 0.27, p < 0.0001), SHBG (MD 12.80 nmol/l, 95%
CI 6.22 to 19.38, p < 0.0001) and FAI (MD 3.93, 95% CI
3.54 to 4.32, p < 0.00001) [40]. No effect was found for
fasting insulin. Ravazi and colleagues [48] examined
selenium in addition to pharmaceutical management
(metformin) against metformin plus placebo in 64
Fig. 4 Meta-analysis omega three fish oils for cholesterol in women with PCOS
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women. No evidence of an additive effect was found for
free testosterone, inflammation or pregnancy rates.
Herbal medicines for PCOS One trial reported on
Camellia sinensis (green tea) capsules compared with
placebo for menstrual regularity [33]. Chan and col-
leagues (2006) investigated the proportion of amenor-
rheic women over a three month period (34 women)
[33]. No difference was found between groups. Adverse
effects were not investigated.
Secondary outcomes
Chan and colleagues (2006) reported on secondary
outcomes however data were presented as median differ-
ences and the interquartile range and analysed for
changes over time. Consequently data were not suitable
for inclusion in analyses in this review [33]. No signifi-
cant differences in median values over time were found
for women taking Camellia sinensis or placebo for tes-
tosterone, SHBG, FAI, androstenidione, FSH, LH, BMI,
waist to hip ratio, insulin, glucose, cholesterol,
triglycerides HDL or LDL.
Cimicifuga Racemosa One study examined the com-
bination of Cimicifuga racemosa and the pharmaceutical
agent Clomiphene citrate (clomiphene) against clomi-
phene alone in 194 women [49]. Menstrual regulation or
adverse effects were not reported.
Secondary outcomes
A significant treatment effect was found for the com-
bination group for reduced days to ovulation (MD
−3 days, 95% CI -3.51 to −2.49, p < 0.01), pregnancy
rates (RR 1.98, 95% CI 1.19 to 3.31, p < 0.01), FSHmIU/l
(MD 0.40, 95% CI 0.22 to 0.58, p < 0.01), LH mIU/l (MD
-2.3, 95% CI -2.55 to −2.05, p < 0.01), and reduced mis-
carriage (RR 0.62, 95% CI 0.22 to 1.74, p = 0.36).
Cinnamomum sp. No evidence of a menstrual regulation
effect was found in one study investigating Cinnamomum
sp. compared with placebo in 17 women [42]. Four non-
serious adverse events were reported for Cinnamomum
sp. [42]. These included headache, heartburn, menstrual
cramps, nausea and diarrhoea. No adverse events were re-
ported in the second study by Wang and colleagues [52].
Use of a variable dose may explain the different findings for
adverse effects; one investigated 1500 mg of Cinnamomum
sp. per day over six months [42] and the other 1000 mg per
day over eight weeks [52].
Secondary outcomes
Two studies reported on metabolic hormones following
treatment with Cinnamomum sp. compared to placebo
[42, 52]. Primary data were not reported by Wang and col-
leagues and between groups could not be examined [52].
No evidence of a treatment effect for Cinnamomum sp.
was found for insulin resistance (HOMA-IR) or insulin
sensitivity (QUICKI) [42].
Mentha Spicata No data on primary outcomes were
reported.
Secondary outcomes
A significant treatment effect was found for Mentha
spicata compared to Matricaria recutita (chamomile)
tea for reduction in total testosterone in 41 women (MD
0.18 nmol/l, 95% CI -0.34 to −0.02, p = 0.03) [39]. No
significant treatment effects were found for free testos-
terone, hirsutism or the dermatology index quality of life
assessment.
Discussion
This systematic review included 24 randomised con-
trolled trials of 1406 women with PCOS. Seven nutri-
tional supplements and four herbal medicines were
investigated and meta-analyses were reported for cal-
cium plus vitamin D, Cinnamomum sp., inositol (vitamin
B8), omega three fish oils and vitamin D. Menstrual re-
gularity, a defining feature of critical interest to women
with PCOS [25], was examined in only four studies and
no significant treatment effect compared to controls was
found. However secondary outcomes of time to ovula-
tion, ovulation rates, hyperandrogenism, reproductive
and metabolic hormones, waist to hip ratio, cholesterol
and triglycerides were significantly improved by inositol
and total cholesterol was significantly lowered by omega
three fish oils compared to controls. Adverse effects
were reported in seven studies for four nutritional sup-
plements and one herbal medicine. Mild adverse effects
were found for Cinnamomum sp. There were no long
term investigations of safety.
Findings for the primary outcome, menstrual regulation
This review found no single nutritional supplement or
herbal medicine significantly improved the primary out-
come, menstrual regulation. The oral contraceptive pill
(OCP) is first line pharmaceutical treatment for men-
strual regularity in women with PCOS [9], however it is
contraindicated in women with increased cardiovascular
risks [12, 15] and women with PCOS have reported pref-
erences for effective alternatives [15]. Metformin is an
effective alternative however women with PCOS have
reported high rates of unpleasant side effects [13].
There is low quality evidence from RCTs for menstrual
regulation included in this review. Trials were character-
ized by a high risk of selection, performance and detection
biases and an unclear risk of reporting bias. Evidence from
methodologically sound RCTs is needed to examine the
reliability of findings for calcium plus vitamin D compared
with metformin for menstrual regulation.
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Chan (2006) and colleagues found a treatment effect on
the primary outcome in a sub-analysis investigating
Camellia sinensis with a lower proportion of amenorrheic
women at twelve weeks for women taking Camellia sinensis
compared to placebo controls, however differences between
groups were not significant [33]. Findings were limited by
the small sub-group sample size (only 14 women), the study
was underpowered for the number of amenorrheic women
and was assessed as low quality due to not reporting base-
line characteristics of subgroups and for reporting on
medians rather than means.
The findings of this review contribute to the evidence
for Chinese Herbal Medicine (CHM) for oligomenor-
rhoea and amenorrhoea in women with PCOS [23].
Traditional Chinese herbal formulations are another
form of ingestible complementary medicine of interest
to women with PCOS [16]. In that systematic review
which included Chinese and English language papers,
only one small, low quality study investigated menstrual
cyclicity outcomes for CHM and found an improved
menstrual regulation response from the oral contracep-
tive pill (Diane 35) when combined with CHM com-
pared to Diane 35 alone (RR 2.6, 95% CI 1.06 to 6.39,
p = 0.04). We have some low grade evidence to add to
women’s treatment decisions for menstrual regularity;
calcium plus vitamin D, compared to metformin does
not appear to provide any further benefits on this out-
come. We agree that the evidence for ingestible CMs for
menstrual regulation is poor quality and inconclusive
due to the absence of findings from methodologically
sound clinical studies.
Findings for the nutritional supplement inositol
This review provides some support for a therapeutic role
of inositol. As an essential structural component of cell
membranes, inositol is needed for cell membrane signal-
ling functions including those involving neurological
signalling in the brain, second messenger systems and
insulin signal transduction. Impaired insulin signalling in
skeletal muscle and adipose tissue has a pathogenic role
in conditions of insulin resistance [56, 57]. It has been
proposed that ovarian theca cells of women with PCOS
remain sensitive to insulin despite insulin resistance, and
theca cell androgen production continues through an
alternative insulin signal transduction system [58]. Evi-
dence for a range of doses of inositol suggests thera-
peutic supplementation may improve metabolic profile
in women with PCOS in addition to reduced biochem-
ical hyperandrogenism and improved ovulation and
pregnancy rates. However, only one small study included
in this review examined live birth rates and no signifi-
cant improvements were found compared to controls.
As healthy, live birth outcomes are the primary goal of
all interventions for women with PCOS seeking
treatment for infertility there is a need for more high
quality randomised controlled trials to report on this
outcome. Adverse effects of inositol were examined in
only two studies. Despite the likely low risks [59] this
systematic review found no long term investigations
assessing safety, and the evidence of safety is not estab-
lished in women with PCOS.
The findings of this review differ with the systematic
review of hypoglycaemic interventions for women with
PCOS [14]. Tang and colleagues found no evidence for
inositol compared with placebo in two studies for im-
proved ovulation in 327 women (Odds Ratio 5.38, 95%
CI 0.70 to 41.31, I2 81%) [38, 45], or for lowered andro-
gens, metabolic markers or blood lipids in 44 women
[45]. Differences in our findings may be explained by the
variable study inclusion criteria and the number of stud-
ies included in analyses. Tang and colleagues included
studies only investigating the d-chiro isomer form of in-
ositol against placebo or no treatment [14]. This present
review included studies investigating any isometric form
of inositol and active controls.
Well-being and quality of life outcomes
Women are likely to use nutritional supplements and
herbal medicines in addition to conventional pharmaceut-
ical management possibly to improve well-being and qual-
ity of life [16, 60]. No studies investigated well-being or
quality of life (QoL) outcomes and few studies examined
safety for the use of nutritional and herbal supplements in
conjunction with pharmaceutical treatment. Further evi-
dence is needed to inform women’s treatment decisions
and to assess the clinical usefulness of nutritional supple-
ments and herbal medicine for improved well-being and
quality of life in women with PCOS.
Limitations
The inclusion of an English language excluded non-
English language research and indexations. Herbal medi-
cine has a high prevalence of use amongst non-English
speaking cultures and this review was limited by its omis-
sion of non-English language research and databases.
Other limitations of this review include the poor
quality of evidence, the small number of nutritional
supplements and herbal medicine interventions, the
absence of QoL and well-being outcomes and lack of
long term investigations of safety. Key words did not
include individual nutrient and herbal possibilities or
complex herbal formulations and evidence may have
been missed. In addition, methodological weaknesses
lead to the exclusion of many studies and the authors
did not seek further information from researchers of
studies where the median rather than the mean was
reported. Further research using rigorous RCT design
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is needed to inform findings of this systematic
review.
A narrow inclusion criteria of only RCTs that exam-
ined the three diagnostic features of PCOS were speci-
fied for this review. Further literature reviews with
inclusion criteria of other clinical outcomes such as fer-
tility, anthropometric or psychological outcomes may
strengthen the findings found here and better inform cli-
nicians and women’s treatment decisions.
Conclusion
There is no high quality evidence to support the effect-
iveness of nutritional supplements and herbal medicine
for PCOS symptoms and evidence of safety and is lack-
ing. However for two nutritional supplements, there was
some low quality evidence that suggests women with
PCOS may benefit from inositol and omega three fish
oil supplements. Further research is needed.
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